Advances in the development of ribozymes and antisense oligodeoxynucleotides as antiviral agents for human papillomaviruses

Antiviral Therapy

Volumn 8, Issue 4, 2003, Pages 265-278

  Alvarez Salas, Luis Maret ^b   Benítez Hess, Maria Luisa ^b   DiPaolo, Joseph A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; ANTIVIRUS AGENT; HAIRPIN RIBOZYME; HAMMERHEAD RIBOZYME; RIBOZYME; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; CANCER INHIBITION; CELL IMMORTALIZATION; ENZYME MECHANISM; ENZYME STRUCTURE; EPITHELIUM CELL; GENE EXPRESSION; GENE INACTIVATION; GENE TARGETING; GENE THERAPY; GENETIC TRANSCRIPTION; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; MALIGNANT TRANSFORMATION; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SEXUALLY TRANSMITTED DISEASE; TUMOR CELL CULTURE; TUMOR GROWTH; UROGENITAL TRACT INFECTION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; VIRUS E6 GENE; VIRUS E7 GENE; VIRUS GENE; VIRUS INFECTION; VIRUS INHIBITION; VIRUS STRAIN; WART VIRUS;

ANTIVIRAL AGENTS; BASE SEQUENCE; FEMALE; GENE EXPRESSION REGULATION, VIRAL; HUMANS; MOLECULAR SEQUENCE DATA; OLIGODEOXYRIBONUCLEOTIDES; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; REPRESSOR PROTEINS; RNA, ANTISENSE; RNA, CATALYTIC; UTERINE CERVICAL NEOPLASMS;

EID: 0042825268     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (140)

1. Greenstone HL, Nieland JD, de Visser KE, De Bruijn ML, Kirnbauer R, Roden RB, Lowy DR, Kast WM & Schiller JT Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proceedings of the National Academy of Sciences, USA 1998; 95:1800-1805.
2. Harto CD, Pang YY, Roden RB, Hildesheim A, Wang Z, Reynolds MJ, Mast TC, Robinson R, Murphy BR, Karron RA, Dillner J, Schiller JT & Lowy DR. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. Journal of the National Cancer Institute 2001; 93:284-292.
3. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM & Jansen KU. A controlled trial of a human papillomavirus type 16 vaccine. New England Journal of Medicine 2002; 347:1645-1651.
4. Franco EL. Cancer causes revisited: human papillomavirus and cervical neoplasia. Journal of the National Cancer Institute 1995; 87:779-780.
5. Kadish AS, Timmins P, Wang Y, Ho GY, Burk RD, Ketz J, He W, Romney SL, Johnson A, Angeletti R & Abadi M. Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide. Cancer Epidemiology, Biomarkers & Prevention 2002; 11:483-488.
6. Hernandez-Avila M, Lazcano-Ponce EC, Berumen-Campos J, Cruz-Valdez A, Alonso de Ruiz PP & Gonzalez-Lira G. Human papilloma virus 16-18 infection and cervical cancer in Mexico: a case-control study. Archives of Medical Research 1997; 28:265-271.
7. Koutsky L. Epidemiology of genital human papillomavirus infection. American Journal of Medicine 1997; 102:3-8.
8. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R & Shah KV. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. Journal of the National Cancer Institute 1995; 87:796-802.
9. Zur Hausen H. Papillomavirus infections - a major cause of human cancers. Biochimica et Biophysica Acta 1996; 1288:F55-78.
10. Lambert PF, Dostatni N, McBride AA, Yaniv M, Howley PM & Arcangioli B. Functional analysis of the papilloma virus E2 trans-activator in Saccharomyces cerevisiae. Genes & Development 1989; 3:38-48.
11. Chiang CM, Ustav M, Stenlund A, Ho TF, Broker TR & Chow LT. Viral E1 and E2 proteins support replication of homologous and heterologous papillomaviral origins. Proceedings of the National Academy of Sciences, USA 1992; 89:5799-5803.
12. Kuo SR, Liu JS, Broker TR & Chow LT. Cell-free replication of the human papillomavirus DNA with homologous viral E1 and E2 proteins and human cell extracts. Journal of Biological Chemistry 1994; 269:24058-24065.
13. Pirisi L, Yasumoto S, Feller M, Doniger J & DiPaolo JA. Transformation of human fibroblasts and keratinocytes with human papillomavirus type 16 DNA. Journal of Virology 1987; 61:1061-1066.
14. Durst M, Dzarlieva-Petrusevska RT, Boukamp P, Fusenig NE & Gissmann L. Molecular and cytogenetic analysis of immortalized human primary keratinocytes obtained after transfection with human papillomavirus type 16 DNA. Oncogene 1987; 1:251-256.
15. Broker TR. Structure and genetic expression of papillomaviruses. Obstetrics & Gynecology Clinics of North America 1987; 14:329-348.
16. Zimmermann H, Degenkolbe R, Bernard HU & O'Connor MJ. The human papillomavirus type 16 E6 oncoprotein can down-regulate p53 activity by targeting the transcriptional coactivator CBP/p300. Journal of Virology 1999; 73:6209-6219.
17. Etscheid BG, Foster SA & Galloway DA. The E6 protein of human papillomavirus type 16 functions as a transcriptional repressor in a mechanism independent of the tumor suppressor protein, p53. Virology 1994; 205:583-585.
18. Werness BA, Levine AJ & Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990; 248:76-79.
19. Scheffner M, Huibregtse JM, Vierstra RD & Howlev PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993; 75:495-505.
20. Munger K, Basile JR, Duensing S, Eichten A, Gonzalez SL, Grace M & Zacny VL. Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene 2001; 20:7888-7898.
21. Dyson N, Howley PM, Munger K & Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989; 243:934-937.
22. Duensing S, Duensing A, Flores ER, Do A, Lambert PF & Munger K. Centrosome abnormalities and genomic instability by episomal expression of human papillomavirus type 16 in raft cultures of human keratinocytes. Journal of Virology 2001; 75:7712-7716.
23. Munger K & Phelps WC. The human papillomavirus E7 protein as a transforming and transactivating factor. Biochimica et Biophysica Acta 1993; 1155:111-123.
24. Duensing S & Munger K. The human papillomavirus type 16 E6 and E7 oncoproteins independently induce numerical and structural chromosome instability. Cancer Research 2002; 62:7075-7082.
25. Bonham MA, Brown S, Boyd AL, Brown PH, Bruckenstein DA, Hanvey JC, Thomson SA, Pipe A, Hassman F & Bisi JE. An assessment of the antisense properties of RNase H-competent and steric-blocking oligomers. Nucleic Acids Research 1995; 23:1197-1203.
26. Haseloff J & Gerlach WL. Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature 1988; 334:585-591.
27. Hampel A & Tritz R. RNA catalytic properties of the minimum (-)sTRSV sequence. Biochemistry 1989; 28:4929-4933.
28. Rossi JJ. Ribozymes. Current Opinion on Biotechnology 1992; 3:3-7.
29. Eckstein F, Kore AR & Nakamaye KL. In vitro selection of hammerhead ribozyme sequence variants. Chembiochem 2001; 2:629-635.
30. Cech TR. Self-splicing of group I introns. Annual Review of Biochemistry 1990; 59:543-568.
31. Guerrier-Takada C, Gardiner K, Marsh T, Pace N & Altman S. The RNA moiety of ribonuclease P is the catalytic subunit of the enzyme. Cell 1983; 35:849-857.
32. Haseloff J & Gerlach WL. Sequences required for self-catalysed cleavage of the satellite RNA of tobacco ringspot virus. Gene 1989; 82:43-52.
33. Hutchins CJ, Rathjen PD, Forster AC & Symons RH. Self-cleavage of plus and minus RNA transcripts of avocado sunblotch viroid. Nucleic Acids Research 1986; 14:3627-3640.
34. Latham JA, Zaug AJ & Cech TR. Self-splicing and enzymatic cleavage of RNA by a group I intervening sequence. Methods in Enzymology 1990; 181:558-569.
35. Cech TR, Herschlag D, Piccirilli JA & Pyle AM. RNA catalysis by a group I ribozyme. Developing a model for transition state stabilization. Journal of Biological Chemistry 1992; 267:17479-17482.
36. Saville BJ & Collins RA. A site-specific self-cleavage reaction performed by a novel RNA in Neurospora mitochondria. Cell 1990; 61:685-696.
37. Branch AD & Robertson HD. Efficient trans cleavage and a common structural motif for the ribozymes of the human hepatitis delta agent. Proceedings of the National Academy of Sciences, USA 1991; 88:10163-10167.
38. Kruger K, Grabowski PJ, Zaug AJ, Sands J, Gottschling DE & Cech TR. Self-splicing RNA: autoexcision and autocyclization of the ribosomal RNA intervining sequence of Tetrahymena. Cell 1982; 31:147-157.
39. Rossi JJ. Practical ribozymes. Making ribozymes work in cells. Current Biology 1994; 4:469-471.
40. Symons RH. Small catalytic RNAs. Annual Review of Biochemistry 1992; 61:641-671.
41. Hampel A. The hairpin ribozyme: discovery, two-dimensional model, and development for gene therapy. Progress in Nucleic Acid Research & Molecular Biology 1998; 58:1-39.
42. Yu Q & Burke JM. Design of hairpin ribozymes for in vitro and cellular applications. Methods in Molecular Biology 1997; 74:161-169.
43. Hampel A, Tritz R, Hicks M & Cruz P. 'Hairpin' catalytic RNA model: evidence for helices and sequence requirement for substrate RNA. Nucleic Acids Research 1990; 18:299-304.
44. Anderson P, Monforte J, Tritz R, Nesbitt S, Hearst J & Hampel A. Mutagenesis of the hairpin ribozyme. Nucleic Acids Research 1994; 22:1096-1100.
45. DeYoung M, Siwkowski AM, Lian Y & Hampel A. Catalytic properties of hairpin ribozymes derived from Chicory yellow mottle virus and arabis mosaic virus satellite RNAs. Biochemistry 1995; 34:15785-15791.
46. Hernandez C, Daros JA, Elena SF, Moya A & Flores R. The strands of both polarities of a small circular RNA from carnation self-cleave in vitro through alternative double- and single-hammerhead structures. Nucleic Acids Research 1992; 20:6323-6329.
47. Navarro B & Flores R. Chrysanthemum chlorotic mottle viroid: unusual structural properties of a subgroup of self-cleaving viroids with hammerhead ribozymes. Proceedings of the National Academy of Sciences, USA 1997; 94:11262-11267.
48. Forster AC & Symons RH. Self-cleavage of plus and minus RNAs of a virusoid and a structural model for the active sites. Cell 1987; 49:211-220.
49. Epstein LM & Gall JG. Self-cleaving transcripts of satellite DNA from the newt. Cell 1987; 48:535-543.
50. Vaish NK, Kore AR & Eckstein F. Recent developments in the hammerhead ribozyme field. Nucleic Acids Research 1998; 26:5237-5242.
51. Kore AR, Vaish NK, Kutzke U & Eckstein F. Sequence specificity of the hammerhead ribozyme revisited; the NHH rule. Nucleic Acids Research 1998; 26:4116-4120.
52. Uhlenbeck OC. A small catalytic oligoribonucleotide. Nature 1987; 328:596-600.
53. Sheldon CC & Symons RH. Mutagenesis analysis of a self-cleaving RNA. Nucleic Acids Research 1989; 17:5679-5685.
54. Prody GA, Bakos JT, Buzayan JM, Schneider IR & Bruening G. Autolytic processing of dimeric plant virus satellite RNA. Science 1986; 321:1577-1580.
55. Ambros S & Flores R. In vitro and in vivo self-cleavage of a viroid RNA with a mutation in the hammerhead catalytic pocket. Nucleic Acids Research 1998; 26:1877-1883.
56. Sun LQ, Cairns MJ, Saravolac EG, Baker A & Gerlach WL. Catalytic nucleic acids: from lab to applications. Pharmacological Reviews 2000; 52:325-347.
57. Fedor MJ & Uhlenbeck OC. Kinetics of intermolecular cleavage by hammerhead ribozymes. Biochemistry 1992; 31:12042-12054.
58. Ananvoranich S, Fiola K, Ouellet J, Deschenes P & Perreault JP. Kinetic analysis of bimolecular hepatitis delta ribozyme. Methods in Enzymology 2001; 341:553-566.
59. Walter NG. Structural dynamics of catalytic RNA highlighted by fluorescence resonance energy transfer. Methods 2001; 25:19-30.
60. Pley HW, Flaherty KM & McKay DB. Three-dimensional structure of a hammerhead ribozyme. Nature 1994; 372:68-74.
61. Scott WG, Finch JT & Klug A. The crystal structure of an all-RNA hammerhead ribozyme. Nucleic Acids Symposium Series 1995; 214-216.
62. Rupert PB & Ferre-D'Amare AR. Crystal structure of a hairpin ribozyme-inhibitor complex with implications for catalysis. Nature 2001; 410:780-786.
63. Berzal-Herranz A, Joseph S, Chowrira BM, Butcher SE & Burke JM. Essential nucleotide sequences and secondary structure elements of the hairpin ribozyme. EMBO Journal 1993; 12:2567-2573.
64. Ryder SP & Strobel SA. Comparative analysis of hairpin ribozyme structures and interference data. Nucleic Acids Research 2002; 30:1287-1291.
65. Wedekind JE & McKay DB. Crystallographic structures of the hammerhead ribozyme: relationship to ribozyme folding and catalysis. Annual Review of Biophysics & Biomolecular Structure 1998; 27:475-502.
66. Finzi D & Siliciano RF. Viral dynamics in HIV-1 infection. Cell 1998; 93:665-671.
67. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA & Hahn BH. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373:117-122.
68. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM & Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373:123-126.
69. Trono D. HIV accessory proteins: leading roles for the supporting cast. Cell 1995; 82:189-192.
70. Emerman M & Malim MH. HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology. Science 1998; 280:1880-1884.
71. Dahm SC, Derrick WB & Uhlenbeck OC. Evidence for the role of solvated metal hydroxide in the hammerhead cleavage mechanism. Biochemistry 1993; 32:13040-13045.
72. Murray JB, Terwey DP, Maloney L, Karpeiskv A, Usman N, Beigelman L & Scott WG. The structural basis of hammerhead ribozyme self-cleavage. Cell 1998; 92:665-673.
73. O'Rear JL, Wang S, Feig AL, Beigelman L, Uhlenbeck OC & Herschlag D. Comparison of the hammerhead cleavage reactions stimulated by monovalent and divalent cations. RNA 2001; 7:537-545.
74. Takagi Y, Warashina M, Stec WJ, Yoshinari K & Taira K. Recent advances in the elucidation of the mechanisms of action of ribozymes, Nucleic Acids Research 2001; 29:1815-1834.
75. Davis ME. Non-viral gene delivery systems. Current Opinion on Biotechnology 2002; 13:128-131.
76. Seymour LW. Delivering gene therapy. Journal of Drug Targeting 2002; 10:91.
77. Felgner JH, Kumar R, Sridhar CN, Wheeler CJ, Tsai YJ, Border R, Ramsey P, Martin M & Felgner PL. Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. Journal of Biological Chemistry 1994; 269:2550-2561.
78. Christoffersen RE & Marr JJ. Ribozymes as human therapeutic agents. Journal of Medicinal Chemistry 1995; 38:2023-2037.
79. Bettinger T, Carlisle RC, Read ML, Ogris M & Seymour LW. Peptide-mediated RNA delivery: a novel approach for enhanced transfection of primary and post-mitotic cells. Nucleic Acids Research 2001; 29:3882-3891.
80. Aigner A, Fischer D, Merdan T, Brus C, Kissel T & Czubayko F. Delivery of unmodified bioactive ribozymes by an RNA-stabilizing polyethylenimine (LMW-PEI) efficiently down-regulates gene expression. Gene Therapy 2002; 9:1700-1707.
81. Usman N & Blatt LM. Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics. Journal of Clinical Investigation 2000; 106:1197-1202.
82. Beigelman L, McSwiggen JA, Draper KG, Gonzalez C, Jensen K, Karpeisky AM, Modak AS, Matulic-Adamic J, DiRenzo AB & Haeberli P. Chemical modification of hammerhead ribozymes. Catalytic activity and nuclease resistance. Journal of Biological Chemistry 1995; 270:25702-25708.
83. Lee PA, Blatt LM, Blanchard KS, Bouhana KS, Pavco PA, Bellon L & Sandberg JA. Pharmacokinetics and tissue distribution of a ribozyme directed against hepatitis C virus RNA following subcutaneous or intravenous administration in mice. Hepatology 2000; 32:640-646.
84. Morrissey DV, Lee PA, Johnson DA, Overly SL, McSwiggen JA, Beigelman L, Mokler VR, Maloney L, Vargeese C, Bowman K, O'Brien JT, Shaffer CS, Conrad A, Schmid P, Morrey JD, Macejak DG, Pavco PA & Blatt LM. Characterization of nuclease-resistant ribozymes directed against hepatitis B virus RNA. Journal of Viral Hepatitis 2002; 9:411-418.
85. Thompson JD, Ayers DF, Malmstrom TA, McKenzie TL, Ganousis L, Chowrira BM, Couture L & Stinchcomb DT. Improved accumulation and activity of ribozymes expressed from a tRNA-based RNA polymerase III promoter. Nucleic Acids Research 1995; 23:2259-2268.
86. Bertrand E, Castanotto D, Zhou C, Carbonnelle C, Lee NS, Good P, Chatterjee S, Grange T, Pictet R, Kohn D, Engelke D & Rossi JJ. The expression cassette determines the functional activity of ribozymes in mammalian cells by controlling their intracellular localization. RNA 1997; 3:75-88.
87. Taira K, Nakagawa K, Nishikawa S & Furukawa K. Construction of a novel RNA-transcript-trimming plasmid which can be used both in vitro in place of run-off and (G)-free transcriptions and in vivo as multi-sequences trascription vectors. Nucleic Acids Research 1991; 19:5125-5130.
88. Cotten M & Birnstiel ML. Ribozyme mediated destruction of RNA in vivo. EMBO Journal 1989; 8:3861-3866.
89. Kuwabara T, Warashina M, Tanabe T, Tani K, Asano S & Taira K. A novel allosterically trans-activated ribozyme, the maxizyme, with exceptional specificity in vitro and in vivo. Molecular Cell 1998; 2:617-627.
90. Yu M, Ojwang J, Yamada O, Hampel A, Rapapport J, Looney D & Wong-Staal F. A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus type 1. Proceedings of the National Academy of Sciences, USA 1993; 90:6340-6344.
91. Alvarez-Salas LM, Cullinan AE, Siwkowski A, Hampel A & DiPaolo JA. Inhibition of HPV-16 E6/E7 immortalization of normal keratinocytes by hairpin ribozymes. Proceedings of the National Academy of Sciences, USA 1998; 95:1189-1194.
92. Ilves H, Barske C, Junker U, Bohnlein E & Veres G. Retroviral vectors designed for targeted expression of RNA polymerase III-driven transcripts: a comparative study. Gene 1996; 171:203-208.
93. Wraight CJ & White PJ. Antisense oligonucleotides in cutaneous therapy. Pharmacological Therapy 2001; 90:89-104.
94. Ding Y & Lawrence CE. Statistical prediction of singlestranded regions in RNA secondary structure and application to predicting effective antisense target sites and beyond. Nucleic Acids Research 2001; 29:1034-1046.
95. Mathews DH, Burkard ME, Freier SM, Wyatt JR & Turner DH. Predicting oligonucleotide affinity to nucleic acid targets. RNA 1999; 5:1458-1469.
96. Mathews DH & Turner DH. Dynalign: an algorithm for finding the secondary structure common to two RNA sequences. Journal of Molecular Biology 2002; 317:191-203.
97. Monia BP, Johnston JF, Geiger T, Muller M & Fabbro D. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nature Medicine 1996; 2:668-675.
98. Dean NM, McKay R, Condon TP & Bennett CE Inhibition of protein kinase C-a expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters. Journal of Biological Chemistry 1994; 269:16416-16424.
99. Milner N, Mir KU & Southern EM. Selecting effective antisense reagents on combinatorial oligonucleotide arrays. Nature Biotechnology 1997; 15:537-541.
100. Monia BP, Sasmor H, Johnston JF, Freier SM, Lesnik EA, Muller M, Geiger T, Altmann KH, Moser H & Fabbro D. Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo. Proceedings of the National Academy of Sciences, USA 1996; 93:15481-15484.
101. Ho SP, Britton DH, Stone BA, Behrens DL, Leffet LM, Hobbs FW, Miller JA & Trainor GL. Potent antisense oligonucleotides to the human multidrug resistance-1 mRNA are rationally selected by mapping RNA-accessible sites with oligonucleotide libraries. Nucleic Acids Research 1996; 24:1901-1907.
102. Pierce ML & Ruffner DE. Construction of a directed hammerhead ribozyme library: towards the identification of optimal target sites for antisense-mediated gene inhibition. Nucleic Acids Research 1998; 26:5093-5101.
103. Ho SP, Britton DH, Bao Y & Scully MS. RNA mapping: selection of potent oligonucleotide sequences for antisense experiments. Methods in Enzymology 2000; 314:168-183.
104. Wisotzkey JD, Krizenoskas A, DiAngelo S & Kreider JW. Cleavage of cottontail rabbit papillomavirus E7 RNA with an anti-E7 ribozyme. Biochemical & Biophysical Research Communications 1993; 192:833-839.
105. He YK, Lu CD & Qi GR. In vitro cleavage of HPV16 E6 and E7 RNA fragments by synthetic ribozymes and transcribed ribozymes from RNA-trimming plasmids. FEBS Letters 1993; 322:21-24.
106. Lu D, Chatterjee S, Brar D & Wong KK Jr. Ribozyme-mediated in vitro cleavage of transcripts arising from the major transforming genes of human papillomavirus type 16. Cancer Gene Therapy 1994; 1:267-277.
107. Chen Z, Kamath P, Zhang S, Weil MM & Shillitoe EJ. Effectiveness of three ribozymes for cleavage of an RNA transcript from human papillomavirus type 18. Cancer Gene Therapy 1995; 2:263-271.
108. Chowrira BM, Berzal-Herranz A & Burke JM. Ionic requirements for RNA binding, cleavage, and ligation by the hairpin ribozyme. Biochemistry 1993; 32:1088-1095.
109. Alvarez-Salas LM, Wilczynski SP, Burger RA, Monk BJ & DiPaolo JA. Polymorphism of the HPV-16 E6 gene of cervical carcinoma. International Journal of Oncology 1995; 7:261-266.
110. Ojwang JO, Hampel A, Looney DJ, Wong-Staal F & Rappaport J. Inhibition of human immunodeficiency virus type 1 expression by a hairpin ribozyme. Proceedings of the National Academy of Sciences, USA 1992; 89:10802-10806.
111. Good PD, Krikos AJ, Li SX, Bertrand E, Lee NS, Giver L, Ellington A, Zaia JA, Rossi JJ & Engelke DR. Expression of small, therapeutic RNAs in human cell nuclei. Gene Therapy 1997; 4:45-54.
112. Berzal-Herranz A, Joseph S & Burke JM. In vitro selection of active hairpin ribozymes by sequential RNA-catalyzed cleavage and ligation reactions. Genes & Development 1992; 6:129-134.
113. Bernard HU, Chan SY & Delius H. Evolution of papillomaviruses. Current Topics in Microbiology & Immunology 1994; 186:33-54.
114. de Villiers EM. Papillomavirus and HPV typing. Clinical Dermatology 1997; 15:199-206.
115. Ohkawa J, Yuyama N, Takebe Y, Nishikawa S & Taira K. Importance of independence in ribozyme reactions: kinetic behavior of trimmed and of simply connected multiple ribozymes with potential activity against human immunodeficiency virus. Proceedings of the National Academy of Sciences, USA 1993; 90:11302-11306.
116. Taira K, Oda M, Shinshi H, Maeda H & Furukawa K. Construction of a novel artificial-ribozyme-releasing plasmid. Protein Engineering 1990; 3:733-737.
117. Ohkawa J, Yuyama N, Takebe Y, Nisikawa S, Homann M, Sczakiel G & Taira K. Multiple site-specific cleavage of HIV RNA by transcribed ribozymes from shotgun-type trimming plasmid. Nucleic Acids Symposium Series 1993; 121-122.
118. Benedict CM, Pan W, Loy SE & Clawson GA. Triple ribozyme-mediated down-regulation of the retinoblastoma gene. Cardnogenesis 1998; 19:1223-1230.
119. Sczakiel G & Far RK. The role of target accessibility for antisense inhibition. Current Opinion on Molecular Therapy 2002; 4:149-153.
120. Zamecnik PC & Stephenson ML. Inhibition of Rous sarcoma virus replication and cell transformation bv a specific oligodeoxynucleotide. Proceedings of the National Academy of Sciences, USA 1978; 75:280-284.
121. Agrawal S & Zhang R. Pharmacokinetics of oligonucleotides. Ciba Foundation Symposium 1997; 209:60-75.
122. Wagner RW, Matteucci MD, Lewis JG, Gutierrez AJ, Moulds C & Froehler BC. Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines. Science 1993; 260:1510-1513.
123. Bennett CF. Antisense oligonucleotides: is the glass half full or half empty? Biochemical Pharmacology 1998; 55:9-19.
124. Mulamba GB, Hu A, Azad RF, Anderson KP & Coen DM. Human cytomegalovirus mutant with sequence-dependent resistance to the phosphorothioate oligonucleotide fomivirsen (ISIS 2922). Antimicrobial Agents & Chemotherapy 1998; 42:971-973.
125. Anderson KP, Fox MC, Brown-Driver V, Martin MJ & Azad RF. Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA. Antimicrobial Agents & Chemotherapy 1996; 40:2004-2011.
126. Azad RF, Driver VB, Tanaka K, Crooke RM & Anderson KP. Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region. Antimicrobial Agents & Chemotherapy 1993; 37:1945-1954.
127. Mercatante D & Kole R. Modification of alternative splicing pathways as a potential approach to chemotherapy. Pharmacological Therapy 2000; 85:237-243.
128. Kole R, Sierakowska H, Agrawal S, Zirbes E & Gorman L. Antisense oligonucleotides as tools for repair of the thalassemic beta-globin pre-mRNA in mammalian cells. Nucleic Acids Symposium Series 1997; 120.
129. Agrawal S & Zhao Q. Mixed backbone oligonucleotides: improvement in oligonucleotide-induced toxicity in vivo. Antisense & Nucleic Acid Drug Development 1998; 8:135-139.
130. Sternberger M, Schmiedeknecht A, Kretschmer A, Gebhardt F, Leenders F, Czauderna F, von C, I, Engle M, Giese K, Beigelman L & Klippel A. GeneBlocs are powerful tools to study and delineate signal transduction processes that regulate cell growth and transformation. Antisense & Nucleic Acid Drug Development 2002; 12:131-143.
131. von Knebel Doeberitz M, Oltersdorf T, Schwarz E & Gissmann L. Correlation of modified human papilloma virus early gene expression with altered growth properties in C4-1 cervical carcinoma cells. Cancer Research 1988; 48:3780-3786.
132. von Knebel Doeberitz M, Rittmuller C, Zur Hausen H & Durst M. Inhibition of tumorigenicity of cervical cancer cells in nude mice by HPV E6-E7 antisense RNA. International Journal of Cancer 1992; 51:831-834.
133. Hayashi S, Nagasaka T, Katayama A, Saito I, Hamada H, Kobayashi T, Yokoyama I, Ohtsuka S, Uchida K &- Takagi H. Adenovirus-mediated gene transfer of antisense ribozyme for alpha 1,3 galactosyltransferase gene and alpha (1,2)fucosyltransferase gene in xenotransplantation. Transplantation Proceedings 1997; 29:2213.
134. Choo CK, Ling MT, Suen CK, Chan KW & Kwong YL. Retrovirus-mediated delivery of HPV16 E7 antisense RNA inhibited tumorigenicity of CaSki cells. Gynecologic Oncology 2000; 78:293-301.
135. Steele C, Cowsert LM & Shillitoe EJ. Effects of human papillomavirus type 18-specific antisense oligonucleotides on the transformed phenotype of human carcinoma cell lines. Cancer Research 1993; 53:2330-2337.
136. Tan TM & Ting RC. In vitro and in vivo inhibition of human papillomavirus type 16 E6 and E7 genes. Cancer Research 1995; 55:4599-4605.
137. Kronenwett R & Sczakiel G. Selection of fast-hybridizing complementary RNA species in vitro. Methods in Molecular Biology 1997; 74:281-288.
138. Venturini F, Braspenning J, Homann M, Gissmann L & Sczakiel G. Kinetic selection of HPV 16 E6/E7-directed antisense nucleic acids: anti-proliferative effects on HPV 16-transformed cells. Nucleic Acids Research 1999; 27:1585-1592.
139. Alvarez-Salas LM, Arpawong TE & DiPaolo JA. Growth inhibition of cervical tumor cells by antisense oligodeoxynucleotides directed to the human papillomavirus type 16 E6 gene. Antisense & Nucleic Acid Drug Development 1999; 9:441-450.
140. Joseph S & Burke JM. Optimization of an anti-HIV hairpin ribozyme by in vitro selection. Journal of Biological Chemistry 1993; 268:24515-24518.